Cell Therapy Market Size Report | Share & Trends 2027

Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapy Type (Allogeneic, Autologous); Product (Consumables, Equipment, Systems and Software), Technology (Viral Vector Technology, Genome Editing Technology, Somatic Cell Technology, Cell Immortalization Technology, Cell Plasticity Technology, Three-dimensional Technology), Application (Oncology, Cardiovascular, Orthopedic, Wound Management, Other Applications), End User (Research Institutes, Hospitals, Others)

  • Report Code : TIPRE00009666
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 201
Buy Now

[Research Report] The cell therapy market was projected to grow from US$ 7,260.50 million in 2019 to reach US$ 12,563.23 million by 2027; it is further estimated to record a CAGR of 7.2% from 2020-2027.     

Market Insights and Analyst View:

Cell therapy is a procedure where living and intact cells are injected, implanted, or grafted into the patient's body. This technology relies on replacing dysfunctional cells with healthy functioning ones. Cells mainly used for such advanced therapies are stem cells, because of their ability to differentiate into the specific cells required for repairing damaged or defective tissues or cells. Moreover, cell therapy also has applications in the development of regenerative medicines.

Growth Drivers and Challenges:

Regenerative therapies aim to induce regeneration of cells, tissues, and organs and restore their functions. Increasing number of regenerative medicine applications for human clinical trials are submitted to the Food and Drug Administration (FDA) each year. This is driving the cell therapy market. As per the Alliance for Regenerative Medicine, in 2019 (Q3), 1,052 clinical trials utilizing regenerative medicine were underway globally; 218 cellular therapy trials were underway (41 Phase I, 147 Phase II, 30 Phase III) in 2019. Rapid advancements in the development of regenerative medicines to provide more effective solutions for chronic conditions are driving the market. Cell therapy is one of the fastest-growing segments of the regenerative medicine domain. Novartis’s Kymriah was the first cell therapy solution offered to treat B-cell acute leukemia, which opened opportunities for this emerging treatment therapy. Moreover, RepliCel, a regenerative medicine provider, has a wide range of regenerative medicine products in the pipeline, with three products—RCH-01, RCS-01, and RCT-01—in the development phase. Further, Sernova is engaged in the development of regenerative medicine technologies and has a huge pipeline of products for conditions, such as Diabetes, Hemophilia A, and hyperthyroidism.

Further, chronic diseases such as cardiovascular disorders, neurological disorders, autoimmune disorders, and cancer, are the leading causes of death and disability worldwide. As per the Centers for Disease Control and Prevention, in 2019, nearly 6 in 10 people suffered from at least one chronic disease in the US. Cardiovascular diseases (CVDs) are a significant cause of mortality owing to the hectic lifestyle. As per the World Health Organization (WHO), CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Cancer is among the leading causes of mortality worldwide, and the disease affects a huge population; therefore, it acts as a huge financial burden on society. According to the WHO, in 2018, ~9.6 million deaths occurred due to cancer globally. However, growing research on developing effective treatments for the disease is positively affecting the market growth. Gene therapy and cell therapy are transforming the cancer treatment landscape; for example, Novartis Kymriah is used to treat diffuse large B-cell lymphoma. The launches of more such products would be driving the demand for cell therapy, thus fueling the growth of cell therapy market in the coming years.

However, the high cost of cell therapy products manufacturing is hampering market growth. The price of cell therapy is high because it has a complex manufacturing process and it uses biological components. Furthermore, the cost of consumables and equipment is much higher, which leads to the premium cost of cell therapies. For instance, the cost of the reagent kit offered by Miltenyi Biotec ranges from US$ 500–5,000. Similarly, the capital cost of installing the equipment is nearly US$ 2 million. Thus, the challenges pertaining to cell therapy prices limit the cell therapy market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Cell Therapy Market: Strategic Insights

cell-therapy-market
Market Size Value inUS$ 7,260.50 million in 2019
Market Size Value byUS$ 12,563.23 million by 2027
Growth rateCAGR of 7.2% from 2020 to 2027
Forecast Period2020-2027
Base Year2019
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

Based on therapy type, the global cell therapy market is bifurcated into allogeneic and autologous. The cell therapy market, by product, is segmented into, consumables, equipment, systems and software. The global cell therapy market, based on technology, is segmented into viral vector technology, genome editing technology, somatic cell technology, cell immortalization technology, cell plasticity technology, and three-dimensional technology. Based on application, the global cell therapy market has been segmented into oncology, cardiovascular, orthopedic, wound management, and other applications. Based on end user, the global cell therapy market is segmented into hospitals, research institutes, and others.

The global cell therapy market based on geography is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America)

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Segmental Analysis of the Global Cell Therapy Market:

Based on therapy type, the global cell therapy market is bifurcated into allogeneic and autologous. In 2019, the allogeneic segment held the largest market share in the therapy type segment. Allogeneic therapies are produced in a large number of batches from irrelative donor tissues. Allogeneic therapies are made beforehand in large numbers and are used to treat many patients. As these are produced in large numbers, require to follow Good Manufacturing Practice (GMP), and hence products produced are quality controlled. Manufacturers are focusing on the development of regenerative therapies by increasingly emphasizing innovations. Many of the regenerative therapeutic applications have gained approval for clinical trials in the US, Europe, and the Asia Pacific due to the effectiveness of allogeneic stem cell therapeutics. This approvals for clinical trials are helping market players to launch new product lines to accelerate the overall product demand for stem therapy using allogeneic stem cell therapeutics and increasing demand for allogeneic cell therapy market. However, the autologous segment is expected to grow at the fastest CAGR during the forecast period.

Cell Therapy Market, by Therapy Type – 2019 and 2027

biotechnology
Cell Therapy Market, by Therapy Type – 2019 and 2027
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

The cell therapy market, by product, is segmented into, consumables, equipment, systems and software. In 2019, the consumables held the largest market share in the product segment. Also, the same segment is expected to grow fastest, with the highest CAGR during the forecast period.

The global cell therapy market, based on technology, is segmented into viral vector technology, genome editing technology, somatic cell technology, cell immortalization technology, cell plasticity technology, and three-dimensional technology. The viral vector technology segment held the largest share of the market in 2019. Similarly, the viral vector technology segment is anticipated to register the highest CAGR during the forecast period. 

Based on application, the global cell therapy market has been segmented into oncology, cardiovascular, orthopedic, wound management, and other applications. In 2019, the oncology segment held the largest market share in the application segment. Also, the same segment is expected to witness growth in its demand at the fastest rate, with the highest CAGR during the forecast period.

Based on end user, the global cell therapy market is segmented into hospitals, research institutes, and others. In 2019, the research institutes segment held the largest market share in the end user segment. Also, the same segment is expected to grow in demand, with the highest CAGR during the forecast period.

Regional Analysis:

Based on geography, the global cell therapy market is segmented into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. In 2019, North America held the largest share of the global cell therapy market size, and Asia Pacific is estimated to register the highest CAGR during the forecast period.

In North America, the U.S. is the largest market for cell therapy. The market growth is attributed to increase in research and development, growing adoption of cell therapies such as stem cell, gene, and immune therapies. Growing incidences of genetic and cellular disorders are leading to increasing demand for cell therapies. A 2020 PhRMA report on the cell and gene therapy pipeline found there are 400 cell and gene therapies in development target a broad range of diseases in the United States. These are focused on a variety of diseases and conditions from cancer to genetic disorders to neurologic conditions. As of February 2020, there are nine cell or gene therapy products approved in the US – treating cancer, eye diseases and rare hereditary diseases. Also, the country is experiencing an increasing number of start-ups that are innovating cell therapies. In addition, growing support from the government is enhancing the growth of cell therapies, which is influencing the growth of the market. For instance, as per the American Society of Gene & Cell Therapy (ASGCT), a public organization, provides memberships to scientists, physicians, professionals, and patient advocates engaged in gene and cell therapies. ASGCT aims to enhance knowledge, education, and awareness regarding the clinical application cell and gene therapies.

In addition, the country has maximum numbers of market players that are involved in the research and product development for cell and gene therapies. Market leaders are investing huge amounts in building gene and cell therapy manufacturing plants. For instance, in November 2019, Novartis AG and Pfizer Inc, has invested ~US$ 2 billion for gene therapy manufacturing. Individually Novartis AG has invested US$ 500 million plan, and Pfizer Inc. has invested US$ 600 million to build their respective manufacturing plants. Moreover, companies have introduced their cell therapies in the market. For instance, in May 2019, FDA has approved AveXis‘s (Novartis) Zolgensma treatment for a rare muscular disorder. It is a gene therapy that priced US$ 2 million. The company aims to introduce 40 new gene therapies in the market by the end of 2022. Thus, owing to the factors mentioned above, the market is estimated to dominate in the forecast period.

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the global cell therapy market are listed below:

  1. In November 2020, Novartis received a global license to use Mesoblast’s cell therapy Remestemcel-L in the treatment of COVID-19. The deal lands Mesoblast $50 million upfront and a partner's support that could help address critical quality attribute concerns raised by the FDA.
  2. In July 2020, MEDIPOST completed phase 2a clinical trial of NEUROSTEM for Alzheimer’s disease.
  3. In December 2019, Bristol-Myers Squibb announced its $74-billion acquisition of Celgene to form a newly combined company with eight products of over $1 billion in annual sales and near-term revenue potential of over $15 billion in new launches.
  4. In May 2019, MediWound Ltd. entered into exclusive license and supply agreements with Vericel Corporation to commercialize NexoBrid in North America. NexoBrid was already approved in the European Union and other international markets. Under the terms of the license agreement, Vericel made an upfront payment to MediWound of $17.5 million, with an additional $7.5 million payment contingent upon U.S. BLA approval.
  5. In February 2016, JCR Pharmaceuticals Co. Ltd., launched its mesenchymal stem cell product TEMCELL HS Inj., to treat acute graft versus host disease (aGVHD) in children and adults in Japan.

Covid-19 Impact:

The cell therapy market witnessed some shortfall at the beginning of COVID-19 crisis. Some of the factors include disruption in supply chain and demand due to lock down. However, the demand for the cell therapy increased drastically owing to supportive government initiatives. For instance, UK government has allotted 100 million Euros funds to the Cell and Gene Therapy Catapult Manufacturing Innovation Centre to expedite the production of a vaccine for COVID-19 in the UK. Additionally, during the initial phase of COVID-19 crisis, due to lockdown and supply chain disruptions the demand for cell therapy was disrupted owing to change in customer behaviors. As the crisis moved forward healthcare professionals realized that development of novel therapies using innovative technologies is essential to mitigate this unprecedented crisis. For instance, FDA has created a unique emergency program for possible COVID-19 therapies, the Coronavirus Treatment Acceleration Program (CTAP). The program uses focus on methods to drive new treatments to patients as soon as possible. At the same time finding out whether they are helpful or harmful.

Furthermore, The FDA cleared an investigational new drug application for ALVR109 by AlloVir, Inc. for the treatment of high-risk adults with COVID-19 infection in September, 2020. Various stem cell therapies, aimed at boosting patients' immune systems and eliminating the virus offered significant growth prospects for the market. For instance, Lattice Biologics in collaboration with Alumina Partners has accelerated phase 1 clinical trials for its stem cell-based AminioBoost therapies of COVID-19. In addition, FDA has also approved a clinical trial to study COVID-19 patients administered with umbilical cord-derived mesenchymal stem cells, which prevents lung inflammation. All such developments fueled the demand for cell therapy market.

Competitive Landscape and Key Companies:

There are various prominent players operating in the global cell therapy market. Top 10 cell therapy companies are Vericel Corporation, MEDIPOST, NuVasive Inc., Mesoblast Limited, JCR Pharmaceuticals Co. Ltd., Smith & Nephew, Bristol-Myers Squibb Company, Cells for Cells, Stemedica Cell Technologies Inc, and Castle Creek Biosciences Inc., among others. These companies focus on various new product developments and geographical expansions. This helps them to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence which allows them to serve a large set of customers. Also, it offers opportunity to increase their market share.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Therapy Type, Product, Technology, Application, End User

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What is cell therapy?

Cell therapy is a procedure where living and intact cells are injected, implanted, or grafted into the patient's body. This technology relies on replacing dysfunctional cells with healthy functioning ones. Cells mainly used for such advanced therapies are stem cells, because of their ability to differentiate into the specific cells required for repairing damaged or defective tissues or cells. Moreover, cell therapy also has applications in the development of regenerative medicines.

What are the driving factors for the cell therapy market across the globe?

The growth of the market is attributed to increasing prevalence of chronic diseases, rising adoption of regenerative medicines, and increasing number of approvals for cell-based therapies. However, the high cost of cell therapy manufacturing hinders the growth of the market.

What is the regional market scenario of cell therapy?

Global cell therapy market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. The North American region is the largest shareholder and the Asia Pacific is the fastest growing market for cell therapy. The market growth in the North American region is expected due to increasing investment in research activities, and product launches.

The List of Companies - Cell Therapy Market

  1. Vericel Corporation
  2. MEDIPOST
  3. NuVasive, Inc.
  4. Mesoblast Limited
  5. JCR Pharmaceuticals Co. Ltd.
  6. Smith & Nephew
  7. Bristol-Myers Squibb Company
  8. Cells for Cells
  9. Stemedica Cell Technologies, Inc,
  10. Castle Creek Biosciences, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Cell Therapy Market